Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. (Q44671794)

5 December 2017

title

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. (English)

1 reference

5 December 2017

1 reference

2

Namiki Izumi

1 reference

5 December 2017

Yasuhiro Asahina

1

1 reference

5 December 2017

Masakatsu Uchihara

3

1 reference

5 December 2017

Osamu Noguchi

4

1 reference

5 December 2017

Yuki Nishimura

5

1 reference

5 December 2017

Kazunari Inoue

6

1 reference

5 December 2017

Ken Ueda

7

1 reference

5 December 2017

Kaoru Tsuchiya

8

1 reference

5 December 2017

Kosei Hamano

9

1 reference

5 December 2017

Jun Itakura

10

1 reference

5 December 2017

Shozo Miyake

11

1 reference

5 December 2017

publication date

1 December 2003

1 reference

5 December 2017

published in

Journal of Hepatology

1 reference

5 December 2017

volume

39

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

1063-1069

1 reference

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B viral genotypes and lamivudine resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

Complete nucleotide sequences of hepatitis B virus genomes associated with epidemic fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900467-7

7 January 2021

10.1016/S0168-8278(03)00467-7

Identifiers

DOI

1 reference

5 December 2017

1 reference